Nektar Therapeutics (NASDAQ: NKTR) is -16.12% lower on its value in year-to-date trading and has touched a low of $0.65 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NKTR stock was last observed hovering at around $0.87 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $0.78, the stock is -6.31% and -14.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.36 million and changing -10.38% at the moment leaves the stock -34.77% off its SMA200. NKTR registered 14.32% gain for a year compared to 6-month loss of -42.21%.
The stock witnessed a -10.89% gain in the last 1 month and extending the period to 3 months gives it a -22.76%, and is -21.99% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.05% over the week and 10.69% over the month.
Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $143.90M and $93.14M in sales. Profit margin for the company is -180.70%. Distance from 52-week low is 20.02% and -59.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.09%).
The EPS is expected to grow by 51.03% this year
The shares outstanding are 184.46M, and float is at 177.74M with Short Float at 3.24%.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $$22.17 million. The investor’s holdings represent 8.5599 of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $$18.79 million to account for 7.7823 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.6587 and valued at over $$16.08 million, while SAMLYN CAPITAL, LLC holds 4.529 of the shares totaling 9.46 million with a market value of $$11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Zalevsky Jonathan, the company’s Chief R&D Officer. SEC filings show that Zalevsky Jonathan sold 10,300 shares of the company’s common stock on Feb 19 ’25 at a price of $1.01 per share for a total of $10403.0. Following the sale, the insider now owns 0.32 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Feb 19 ’25 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 11,040 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $1.01 per share for $11150.0. Following the transaction, the insider now directly holds 0.32 million shares of the NKTR stock.
Still, SEC filings show that on Feb 19 ’25, ROBIN HOWARD W (President & CEO) disposed off 23,774 shares at an average price of $1.01 for $24012.0. The insider now directly holds 1,086,901 shares of Nektar Therapeutics (NKTR).
